Enhanced DNL is a major contributor to hepatic steatosis both in these 2 mouse models of genetic obesity and in obese patients with NAFLD (8), suggesting that inhibition of DNL by hepatic FASN deficiency may ameliorate hepatic steatosis in a manner dependent on the extent of the enhancement of DNL. Here, FASN is linked to metabolic dysfunction-associated steatotic liver disease.